738 – Novel Quinazoline Derivatives Targeting SARS-CoV-2 RdRp With In Vitro and In Vivo Efficacy
Background Currently, direct-acting antivirals for SARS-CoV-2, such as remdesivir, molnupiravir, and nirmatrelvir, are widely used in clinical settings. These agents reduce viral load and mitigate disease severity and mortality. However, drug-resistant variants continue to emerge, highlighting the need for novel small-molecule antivirals that can be co-administered with existing therapies. Methods We synthesized more than 400…